Non-neural phenotype of spinal and bulbar muscular atrophy: Results from a large cohort of Italian patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 8, 2016, Pages 810-816

  Querin, Giorgia ^a   Bertolin, Cinzia ^a   Da Re, Elisa ^a   Volpe, Marco ^a   Zara, Gabriella ^a   Pegoraro, Elena ^a   Caretta, Nicola ^a   Foresta, Carlo ^a   Silvano, Maria ^a   Corrado, Domenico ^a   Iafrate, Massimo ^a   Angelini, Lorenzo ^a   Sartori, Leonardo ^a   Pennuto, Maria ^b   Gaiani, Alessandra ^a   Bello, Luca ^a   Semplicini, Claudio ^a   Pareyson, Davide ^c   Silani, Vincenzo ^d   Ermani, Mario ^a   Ferlin, Alberto ^a   Sorarù, Gianni ^a   Mandrioli, Jessica ^e   Galasso, Giuliana ^e   Mazzini, Letizia ^f   Romito, Silvia ^g   Tonin, Paola ^h   Scarpelli, Mauro ^h   Ricci, Giulia ⁱ   Siciliano, Gabriele ⁱ   Petrucci, Antonio ^j   Massa, Roberto ^k   Polo, Alberto ^l   Mariotti, Caterina ^c   Sagnelli, Anna ^c   Palmieri, Arianna ^a   Briani, Chiara ^a   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g Verona Hospital   (Italy)

^h UNIVERSITY OF VERONA   (Italy)

ⁱ UNIVERSITY OF PISA   (Italy)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^k UNIVERSITY OF ROME TOR VERGATA   (Italy)

^l Legnago Hospital   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CHOLESTEROL; CREATINE KINASE; FOLLITROPIN; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; TESTOSTERONE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; AGED; ARTICLE; BLADDER OBSTRUCTION; BONE MASS; BULBAR PARALYSIS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; FEMUR; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; INDWELLING CATHETER; INTERNATIONAL PROSTATE SYMPTOM SCORE; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE BIOPSY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SPINAL MUSCULAR ATROPHY; SYMPTOMATOLOGY; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT DISEASE; URODYNAMICS; VIDEORECORDING; ANDROGEN INSENSITIVITY SYNDROME; BLOOD; BONE DENSITY; CASE CONTROL STUDY; COMPLICATION; ITALY; METABOLISM; PATHOLOGY; SKELETAL MUSCLE;

ADULT; AGED; ANDROGEN-INSENSITIVITY SYNDROME; BLOOD GLUCOSE; BONE DENSITY; CASE-CONTROL STUDIES; CREATINE KINASE; HUMANS; ITALY; LIPIDS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR ATROPHY, SPINAL; PHENOTYPE; UROLOGIC DISEASES;

EID: 84947557077     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-311305     Document Type: Article

References (53)

1. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-9.
2. Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006;129:1446-55.
3. Rhodes LE, Freeman BK, Auh S, et al. Clinical features of spinal and bulbar muscular atrophy. Brain 2009;132:3242-51.
4. Grunseich C, Kats IR, Bott LC, et al. Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. Neuromuscul Disord 2014;24:978-81.
5. Adachi H, Katsuno M, Minamiyama M, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005;128:659-70.
6. Katsuno M, Tanaka F, Adachi H, et al. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 2012;99:246-56.
7. Fratta P, Nirmalananthan N, Masset L, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology 2014;82:2077-84.
8. Polo A, Teatini F, D'Anna S, et al. Sensory involvement in X-linked spino-bulbar muscular atrophy (Kennedy's syndrome): an electrophysiological study. J Neurol 1996;243:388-92.
9. Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol 2004;25:1-26.
10. Beitel LK, Alvarado C, Mokhtar S, et al. Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction. Front Neurol 2013;4:53.
11. Li M, Miwa S, Kobayashi Y, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998;44:249-54.
12. Dejager S, Bry-Gauillard H, Bruckert E, et al. A comprehensive endocrine description of Kennedy's Disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002;87:3893-901.
13. Sorarù G, D'Ascenzo C, Polo A, et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci 2008;264:100-5.
14. Sorenson EJ, Klein CJ. Elevated creatine kinase and transaminases in asymptomatic SBMA. Amyotroph Lateral Scler 2007;8:62-4.
15. Querin G, Melacini P, D'Ascenzo C, et al. No evidence of cardiomyopathy in spinal and bulbar muscular atrophy. Acta Neurol Scand 2013;128:30-2.
16. Araki A, Katsuno M, Suzuki K, et al. Brugada syndrome in spinal and bulbar muscular atrophy. Neurology 2014;82:1813-21.
17. Doyu M, Sobue G, Mukai E, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with the size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 1992;32:707-10.
18. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002;166:111-17.
20. Takeuchi Y, Katsuno M, Banno H, et al. Walking capacity evaluated by the 6-Minute Walk Test in spinal and bulbar muscular atrophy. Muscle Nerve 2008;38:964-71.
21. Aiman J, Griffin JE, Gazak JM, et al. Androgen insensitivity as a cause of infertility in otherwise normal men. N Engl J Med 1979;300:223-7.
22. Zuccarello D, Ferlina A, Vinanzi C, et al. Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility. Clin Endocrinol 2008;68:580-8.
23. Plante M, Corcos J, Gregoire I, et al. The International Prostate Symptom Score: physician versus self-administration in the quantification of symptomatology. Urology 1996;47:326-8.
24. Kälkner KM, Kubicek G, Nilsson J, et al. Prostate volume determination: differential volume measurements comparing CT and TRUS. Radiother Oncol 2006;81:179-83.
25. Schäfer W, Abrams P, Liao L, et al, International Continence Society. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261-74.
26. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
27. Leib ES, Lewiecki EM, Binkley N, et al, International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004;7:1-6.
28. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659-70.
29. Dubowitz V. Histological and histochemical stains and reactions. In: Dubowitz V, ed. Muscle biopsy. A practical approach. London, UK: Bailliere Tindall, 1985:19-40.
30. Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 2002;42:323-8.
31. Corona G, Vignozzi L, Rastrelli G, et al. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol 2014;2014:32945.
32. Koritsiadis G, Stravodimos K, Mitropoulos D, et al. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study. BJU Int 2008;101:1542-6.
33. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011;8:483-94.
34. Yu Z, Dadgar N, Albertelli M, et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Investigation 2006;116:2663-72.
35. Monks DA, Johansen JA, Mo K, et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A 2007;104:18259-64.
36. Palazzolo I, Stack C, Kong L, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009;63:316-28.
37. Cortes CJ, Ling SC, Guo LT, et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 2014;82:295-307.
38. Lieberman AP, Yu Z, Murray S, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep 2014;7:774-84.
39. Rocchi C, Greco V, Urbani A, et al. Subclinical autonomic dysfunction in spinobulbar muscular atrophy (Kennedy disease). Muscle Nerve 2011;44:737-40.
40. Jackson GL. Beliefs about osteoporosis. Arch Int Med 1987;147:1845.
41. Dupree K, Dobs A. Osteopenia and male hypogonadism. Rev Urol 2006;6:30-4.
42. Ferlin A, Schipilliti M, Di Mambro A, et al. Osteoporosis in Klinefelter's syndrome. Mol Hum Reprod 2010;16:402-10.
43. Danilovic DL, Correa PH, Costa EM, et al. Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene. Osteoporos Int 2010;18:369-74.
44. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 2010;25:1506-11.
45. Zhang J, Morgan SL, Saag KG. Osteopenia: debates and dilemmas. Curr Rheumatol Rep 2013;15:384.
46. Rufo A, Del Fattore A, Capulli M, et al. Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans. J Bone Miner Res 2011;26:1891-903.
47. Vestergaard P, Glerup H, Steffensen BF, et al. Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med 2001;33:150-5.
48. Joyce NC, Hache LP, Clemens PR. Bone health and associated metabolic complications in neuromuscular diseases. Phys Med Rehabil Clin N Am 2012;23:773-99.
49. Ishizaki F, Koyama T, Sunayashiki T, et al. Control of bone remodeling by nervous system. Bone metabolic changes in neurological diseases. Clin Calcium 2010;20:1841-9.
50. Lloyd SA, Lang CH, Zhang Y, et al. Interdependence of muscle atrophy and bone loss induced by mechanical unloading. Bone Miner Res 2014;29:1118-30.
51. Mariotti C, Castellotti B, Pareyson D, et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromusc Disord 2000;10:391-7.
52. Ni W, Chen S, Qiao K, et al. Genotype-phenotype correlation in Chinese patients with spinal and bulbar muscular atrophy. PloS ONE 2015;10:e0122279.
53. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90.